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TheACEinhibitoryactivitiesofmixturesofFOSHUs(Healthya,Goma-Mugicha,LapisSupport andAmeal)wereexaminedinorder
to identify any antihypertensive interactions. Among combinations of Healthya with other samples that contain active peptides,
only that with Ameal was found to have no inhibitory activity. Enhanced activity was observed in 2 other mixtures. The activity
of a mixture of tea polyphenols and the whey component extracted from an Ameal solution was signiﬁcantly decreased, thus
demonstratingthatwheyproteinloweredtheACEinhibitoryactivityofHealthya.Althoughoraladministrationofteapolyphenols
alone signiﬁcantly decreased SBP in SHR at 2 and 4hr, combined administration with Ameal failed to decrease SBP at the same
time points. In conclusion, the simultaneous intake of tea and FOSHUs that contain active peptides might aﬀect daily self-
antihypertensive management via enhancement or suppression of ACE inhibitory activity.
1.Introduction
Tea polyphenols contained in green tea leaves (Camellia
sinensis L.) are known to have antiviral [1], antioxidative
[2, 3], antimutagenic [4], anticarcinogenic [5], antiobesity
[6], and antihypertensive activities [7–9]. Tea leaves contain
tea polyphenols such as catechins, so regular consumption of
green tea is thought to be beneﬁcial to one’s health.
With rising health consciousness among consumers,
particularattentionhasrecentlyfocusedongreentea’saction
to counter obesity and hypertension, which are diagnostic
criteria for metabolic syndrome [10]. Tea beverages that
contain high levels of tea polyphenols and that are labeled
“For individuals worried about body fat” are being sold in
Japan as foods for speciﬁed health uses (FOSHUs).
Long-term consumption of tea has been reported to
result in antihypertensive activity in spontaneously hyper-
tensive rats (SHRs) [7, 8] while another study reported
antihypertensive activity with a single administration of
tea [9]. The antihypertensive activity of tea polyphenols is
thoughttooccurviatheinhibitionofangiotensin-converting
enzyme(ACE)activity[11].Moreover,otherFOSHUs,many
of which have active components consisting of peptides that
inhibit ACE activity, are marketed to target “individuals with
high blood pressure” [12–14].
Indeed, tea beverages and FOSHUs can be readily
obtained, so there may be instances in which they are con-
sumed together. However, for individuals with high blood
pressure, little is known about the antihypertensive interac-
tion between tea and FOSHUs, which are both thought to
have the same mechanisms of action.
Thus, the aim of the current study was to examine
the antihypertensive interaction when a tea beverage and
a FOSHU “For individuals with high blood pressure”
(Goma-Mugicha, Lapis Support,a n dAmeal)w e r ec o n s u m e d
together.2 ISRN Pharmaceutics
2.MaterialsandMethods
2.1. Materials. The green tea beverage used was Healthya
Green Tea (Kao Corporation, Tokyo). The 3 FOSHU prod-
ucts were Ameal (Calpis Co., Tokyo), which is claimed
to “help maintain a normal blood pressure level” and
contains Val-Pro-Pro as its active ingredient [12], Lapis
Support (Tokiwa Yakuhin Co., Ltd., Yamaguchi, Japan),
which has Val-Tys as its active ingredient [13], and Goma-
Mugicha (Suntory Foods Ltd., Tokyo), which has Leu-Val-
Tys as its active ingredient [14]. Whey protein concentrate
(WPC: Protein, Easy Sports Co., Ltd., Tokyo) was also used.
Polyphenon CG (green tea extract, tea polyphenol content
of at least 30%) was purchased from Mitsui Norin Co.,
Ltd. (Tokyo). Rabbit lung ACE was purchased from Sigma
Chemical Co. (St. Louis, MO). All other chemicals were
obtained from Wako Pure Chemicals Co. (Tokyo).
2.2. Preparation of Ameal. The whey fraction was used to
determine the ACE inhibitory activity of Ameal.T h ew h e y
fraction was obtained as follows [15]. The pH of Ameal
was adjusted to 3.4 by adding 50% lactic acid. The Ameal
was centrifuged at 6,000×g for 10min, 10N NaOH was
added to the supernatant to raise the pH to 8.3, and then
the supernatant was centrifuged at 6,000×g for 10min. The
whey fraction of Ameal was used as a sample.
2.3. Assay of ACE Inhibitory Activity. ACE inhibitory activity
was assayed according to the method of Suzuki et al.
[16]withsomemodiﬁcations.Hippuryl-L-histidyl-L-leucine
(Hip-His-Leu) was dissolved in 400mM phosphate buﬀer
(pH 8.5) containing 300mM NaCl. Next, 0.1mL of 4.7mM
Hip-His-Leu solution was mixed with 0.05mL of sample
solution (Healthya, Goma-Mugicha, Lapis Support, Ameal,
andtheirmixtures)andthenpreincubatedfor5minat37◦C.
The reaction was initiated by the addition of 0.1mL of ACE
dissolved in distilled water (25mU/mL), and the mixture
was incubated for 30min at 37◦C. After the reaction had
been stopped by adding 0.3N NaOH (0.75mL), 0.05mL of
2% o-phthaldialdehyde in methanol was added, the mixture
was left at room temperature for 10min, and then 0.1mL
of 0.1N HCl was added. After incubation for 30min at
room temperature, the amount of liberated His-Leu was
determined by measuring the ﬂuorescent intensity of its
adduct with o-phthaldialdehyde (excitation at 340nm and
emission at 455nm). The extent of inhibitory activity was
calculated as follows:
100 −

B −A
B −C
×100

,( 1 )
where A is the ﬂuorescent intensity in the presence of ACE
andACEinhibitorycomponent,Bistheﬂuorescentintensity
without ACE inhibitory component, and C is the ﬂuorescent
intensity without ACE.
Inhibition was expressed as the concentration of com-
ponent that inhibits 50% of ACE activity (IC50). One unit
of ACE inhibitory activity was expressed as the potency
showing50%ACEinhibitionundertheseconditionsandwas
calculated for one bottle, daily intake, or maximum dosage.
Table 1: ACE inhibitory activity of green tea beverage and FOSHU.
ACE inhibitory activity is shown as mean ± SD, n = 6. ∗The ACE
inhibitory activity is shown in relation to the concentration of tea
polyphenol included in Healthya or functional component in each
FOSHU.
Sample ACE inhibitory activity IC50 (ng/mL)∗
Healthya 64.8 ×103 ±7.3 ×103
Goma-Mugicha 19.36 ±4.87
Lapis Support 76.67 ±11.12
Ameal 882.70 ±72.70
2.4. Measurement of β-Lactoglobulin Concentrations. The
concentration of β-lactoglobulin (β-Lg) was measured using
aF A S P E Km i l k( β-lactoglobulin) kit (Morinaga Institute of
Biological Science, Yokohama, Japan) [17].
2.5. Animals. Male SHRs (SHR/NCrlCrlj) were purchased
from Charles River Japan (Yokohama). The SHRs were kept
in an air-conditioned room at 22–24◦C with 55% humidity
and a 12hr light-dark cycle (lights on at 8:00AM). Food
and water were freely available. After an overnight fast, 2g
of Polyphenon CG were dissolved in distilled water or 6mL
of Ameal and orally administered at a dose of 6mL/kg to
conscious SHRs (body weight: 320–390g, 22–25 weeks old)
using a feeding needle. Following administration, systolic
blood pressure (SBP) was measured every 2hr. SBP after
administration was measured by the tail-cuﬀ method using
an MK-2000 blood pressure monitor (Muromachi Kikai
Ltd., Japan). The studies were performed according to the
guidelines of the Animal Care and Use Committee of Teikyo
University. All experiments conformed to the guidelines
on the ethical use of animals, and all eﬀorts were made
to minimize both the number of animals used in the
experiments and their suﬀering.
2.6. Statistical Analysis. Results are expressed as the mean
and standard deviation (SD). The signiﬁcance of diﬀerences
in ACE inhibitory activity and SBP was analyzed using the
Dunnett test or Tukey test.
3. Results and Discussion
3.1. Eﬀects of Several Mixtures of Tea and FOSHU on
ACE Inhibitory Activity. ACE inhibitory activity (IC50)w a s
detected in all samples (64.8 × 103 ± 7.3 × 103 ng/mL,
19.36 ± 4.87ng/mL, 76.67 ± 11.12ng/mL, and 882.70 ±
72.70ng/mL, resp.) (Table 1). When Healthya was mixed
with one of the FOSHUs, the two mixtures of Healthya
plus Goma-Mugicha and Healthya plus Lapis Support had
enhanced inhibitory activity. The mixture of Healthya plus
Ameal did not have enhanced inhibitory activity. The ACE
inhibitory activity shown in Figure 1 was calculated as IC50
based on the amount of functional components included in
each food product for speciﬁed health uses.
3.2. Eﬀects of a Mixture of Tea and Whey Protein on ACE
Inhibitory Activity. I no r d e rt od e t e r m i n ew h yt h eA C EISRN Pharmaceutics 3
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Figure 1: ACE inhibitory activity of mixtures of Healthya and
FOSHU.ActivityofHealthyawithrespecttoconverting32.5mg/mL
of tea polyphenols (black square) and ACE inhibitory peptides in
a FOSHU (white square: Goma-Mugicha conversion of 10ng/mL
Leu-Val-Tys, Lapis Support conversion of 38ng/mL Val-Tys, and
Ameal conversion of 445ng/mL Val-Pro-Pro) or a mixture of
Healthya andaFOSHU(graysquare).Dataareexpressedasmean ±
SD, n = 3.
0
25
50
75
100
A
C
E
i
n
h
i
b
i
t
o
r
y
a
c
t
i
v
i
t
y
(
%
)
WPC
+ WPC
∗
Healthya Healthya
Figure2:ACEinhibitoryactivityofHealthyawithorwithoutWPC.
Activity of Healthya with respect to converting 65mg/mL of tea
polyphenols (black square), 3mg/mL WPC (white square), or a
mixture of Healthya and WPC (gray square). Data are expressed as
mean ± SD, n = 3. (∗P<0.05, Tukey test).
inhibitory activity of a mixture of Healthya and Ameal was
not enhanced, the elemental composition of each FOSHU
was investigated. The whey fraction used in this experiment
was in fact extracted from an Ameal solution (Goma-
Mugicha and Lapis Support do not contain any ingredients
that originate from milk). Healthya that was prepared to
determine the IC50 was mixed with 3μg/mL WPC, and the
mixture’s rate of ACE inhibitory activity was measured. The
concentration of β-lactoglobulin, the main component of
whey protein [18], was 1.28μg/mL in 3μg/mL WPC and
18.6μg/mL in the whey fraction of Ameal (concentration of
IC50, 445ng/mL Val-Pro-Pro). WPC (3μg/mL, as whey) and
Healthya (as tea polyphenol) were used for measurement.
Examination of the ACE inhibitory activity of a mixture of
whey component and tea polyphenols revealed a signiﬁcant
decrease in the rate of ACE inhibitory activity of Healthya
(56.9 ± 3.2%) as a result of the addition of 3μg/mL WPC
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Figure 3: Time course of hypotensive activity after oral administra-
tionofteapolyphenols(Polyphenon CG)toSHRs.,Distilledwater
(control);  , Ameal; , Polyphenon CG in Ameal;  , Polyphenon
CG in distilled water. The vertical axis represents changes in SBP
from time zero. Changes in SBP from time zero are expressed as the
mean ± SD, n = 7. The baseline SBP before administration was
198.2 ± 3.0mmHg. (∗P<0.05, ∗∗P<0.01 compared to distilled
water, Dunnett’s test.)
(34.9 ± 9.8%: P<0.05) (Figure 2), thus demonstrating that
whey protein lowered the rate of ACE inhibitory activity of
Healthya.
3.3. Eﬀects of Tea Polyphenols and Ameal on Antihypertensive
Activity in SHRs. To evaluate the antihypertensive activity
of the interaction of tea polyphenols and Ameal, the SBP of
SHRs was measured after a single oral administration. The
baseline SBP before administration was 198.2 ± 3.0mmHg.
Tea polyphenols (polyphenon CG, 2g/kg body weight) signif-
icantly lowered SBP 2 and 4hr after administration (155.4 ±
8.4mmHg and 163.8 ± 7.6mmHg, resp.) in comparison to
distilled water (195.3 ± 6.7mmHg and 178.8 ± 5.8mmHg,
resp.) (P<0.05). However, oral administration of polyphe-
nonCGandAmealfailedtodecreaseSBP(178.9 ±4.7mmHg
and 169.2 ± 8.3mmHg, resp.) at the same times (Figure 3).
Therefore, combined administration of Polyphenon CG with
Ameal appears to attenuate antihypertensive activity by
interacting with the whey protein in the Ameal solution.
Though possible mechanisms of the interaction of tea and
milk protein have been discussed in previous reports [19–
21], the actual mechanism is still not clear
In this study, markedly larger amounts of tea catechins
than humans would normally be consumed in typical foods
that were administered to SHRs, and this study examined
the interaction of these catechins. While many health foods
contain much smaller amounts of substances than were
used in the current experiments, numerous products are
being sold in formulations with active components in higher
concentrations than that would normally be consumed. In
addition,theamountofhealthfoodsconsumedissubstantial
when individuals have a strong predilection toward self-
medication. Many such individuals will presumably con-
sume numerous types of health foods at the same time.
Accordingly, large quantities of tea catechins were used in4 ISRN Pharmaceutics
the current study, and the consumption of such amounts is
indeed a possibility.
Moreover, this study focused on blood pressure, which
was found to be aﬀected soon after administration [9],
but interaction between tea catechins and whey protein
attenuated the activity of the two, much like other types
of activity (e.g., antiviral, antioxidative, antimutagenic and
anticarcinogenic, and antiobesity activity) are attenuated.
Based on results of the current study, consuming multiple
health foods at the same time enhanced the activity of indi-
vidual components in some instances. That said, the results
also suggested that such consumption led to interactions,
diminishing the eﬀectiveness of some of the components of
these foods.
4. Conclusion
The ﬁndings of the present study suggest for the ﬁrst time
that interaction between tea and milk protein may attenuate
antihypertensive activity and that the simultaneous intake of
tea and FOSHUs that contain active peptides might aﬀect
daily self-antihypertensive management via the enhance-
ment or suppression of ACE inhibitory activity.
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